Roles of TRPM4 in immune responses in keratinocytes and identification of a novel TRPM4-activating agent.


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
30 04 2023
Historique:
received: 01 02 2023
revised: 13 02 2023
accepted: 22 02 2023
medline: 28 3 2023
pubmed: 6 3 2023
entrez: 5 3 2023
Statut: ppublish

Résumé

The skin is a protective interface between the internal organs and environment and functions not only as a physical barrier but also as an immune organ. However, the immune system in the skin is not fully understood. A member of the thermo-sensitive transient receptor potential (TRP) channel family, TRPM4, which acts as a regulatory receptor in immune cells, was recently reported to be expressed in human skin and keratinocytes. However, the function of TRPM4 in immune responses in keratinocytes has not been investigated. In this study, we found that treatment with BTP2, a known TRPM4 agonist, reduced cytokine production induced by tumor necrosis factor (TNF) α in normal human epidermal keratinocytes and in immortalized human epidermal keratinocytes (HaCaT cells). This cytokine-reducing effect was not observed in TRPM4-deficient HaCaT cells, indicating that TRPM4 contributed to the control of cytokine production in keratinocytes. Furthermore, we identified aluminum potassium sulfate, as a new TRPM4 activating agent. Aluminum potassium sulfate reduced Ca

Identifiants

pubmed: 36871485
pii: S0006-291X(23)00248-6
doi: 10.1016/j.bbrc.2023.02.062
pii:
doi:

Substances chimiques

aluminum sulfate 34S289N54E
Cytokines 0
Tumor Necrosis Factor-alpha 0
TRPM Cation Channels 0
TRPM4 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-9

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts of interest to declare.

Auteurs

Kaori Otsuka Saito (K)

Laboratory of Advanced Cosmetic Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6, Yamadaoka, Suita, Osaka, 565-0871, Japan; Fundamental Research Institute, Mandom Corp., 5-12, Juniken-Cho, Chuo-ku, Osaka, 540-8530, Japan; Laboratory of Mock Up Vaccine, Center for Vaccine and Adjuvant Research (CVAR), National Institutes of Biomedical Innovation, Health and Nutrition (NBIOHN), 7-6-8, Asagi, Saito, Ibaraki-City, Osaka, 567-0085, Japan. Electronic address: saito-ka@phs.osaka-u.ac.jp.

Fumitaka Fujita (F)

Laboratory of Advanced Cosmetic Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6, Yamadaoka, Suita, Osaka, 565-0871, Japan; Fundamental Research Institute, Mandom Corp., 5-12, Juniken-Cho, Chuo-ku, Osaka, 540-8530, Japan; Laboratory of Mock Up Vaccine, Center for Vaccine and Adjuvant Research (CVAR), National Institutes of Biomedical Innovation, Health and Nutrition (NBIOHN), 7-6-8, Asagi, Saito, Ibaraki-City, Osaka, 567-0085, Japan.

Manami Toriyama (M)

Laboratory of Advanced Cosmetic Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6, Yamadaoka, Suita, Osaka, 565-0871, Japan; Laboratory of Mock Up Vaccine, Center for Vaccine and Adjuvant Research (CVAR), National Institutes of Biomedical Innovation, Health and Nutrition (NBIOHN), 7-6-8, Asagi, Saito, Ibaraki-City, Osaka, 567-0085, Japan; Graduate School of Science and Technology, Nara Institute of Science and Technology, 8916-5, Takayama-Cho, Ikoma, Nara, 630-0192, Japan.

Ratna Annisa Utami (RA)

School of Pharmacy, Institut Teknologi Bandung, Jl. Ganesha No. 10, Bandung, 40132, Indonesia.

Zhihan Guo (Z)

Laboratory of Advanced Cosmetic Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6, Yamadaoka, Suita, Osaka, 565-0871, Japan.

Masato Murakami (M)

Laboratory of Advanced Cosmetic Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6, Yamadaoka, Suita, Osaka, 565-0871, Japan; Technical Development Center, Mandom Corp., 5-12, Juniken-Cho, Chuo-ku, Osaka, 540-8530, Japan.

Hiroko Kato (H)

Laboratory of Advanced Cosmetic Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6, Yamadaoka, Suita, Osaka, 565-0871, Japan; Laboratory of Mock Up Vaccine, Center for Vaccine and Adjuvant Research (CVAR), National Institutes of Biomedical Innovation, Health and Nutrition (NBIOHN), 7-6-8, Asagi, Saito, Ibaraki-City, Osaka, 567-0085, Japan.

Yoshiro Suzuki (Y)

Thermal Biology Group, Exploratory Research Center on Life and Living Systems National Institutes of Natural Sciences, 5-1, Aza-higashiyama, Myodaiji, Okazaki, Aichi, 444-8787, Japan; Division of Cell Signaling, National Institute for Physiological Sciences, National Institutes of Natural Sciences, 5-1, Aza-higashiyama, Myodaiji, Okazaki, Aichi, 444-8787, Japan; Department of Physiological Sciences, SOKENDAI (The Graduate University for Advanced Studies), 5-1, Aza-higashiyama, Myodaiji, Okazaki, Aichi, 444-8787, Japan; Department of Physiology, Iwate Medical University, 1-1-1, Idaidori, Yahaba-cho, Shiwa-gun, Iwate, 028-3694, Japan.

Fumihiro Okada (F)

Fundamental Research Institute, Mandom Corp., 5-12, Juniken-Cho, Chuo-ku, Osaka, 540-8530, Japan.

Makoto Tominaga (M)

Thermal Biology Group, Exploratory Research Center on Life and Living Systems National Institutes of Natural Sciences, 5-1, Aza-higashiyama, Myodaiji, Okazaki, Aichi, 444-8787, Japan; Division of Cell Signaling, National Institute for Physiological Sciences, National Institutes of Natural Sciences, 5-1, Aza-higashiyama, Myodaiji, Okazaki, Aichi, 444-8787, Japan; Department of Physiological Sciences, SOKENDAI (The Graduate University for Advanced Studies), 5-1, Aza-higashiyama, Myodaiji, Okazaki, Aichi, 444-8787, Japan.

Ken J Ishii (KJ)

Laboratory of Mock Up Vaccine, Center for Vaccine and Adjuvant Research (CVAR), National Institutes of Biomedical Innovation, Health and Nutrition (NBIOHN), 7-6-8, Asagi, Saito, Ibaraki-City, Osaka, 567-0085, Japan; Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. Electronic address: kenishii@ims.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH